Purchasers have long accused Pfizer—and Sun Pharma's Ranbaxy—of conspiring to keep Lipitor generics off the market with a "reverse payment" agreement. After the Pfizer settlement, the class action lawsuit against Ranbaxy will continue.

The idea to build a company around degrader antibody conjugates—not antibody drug conjugates—had been bubbling for a while. But not just anyone could pick up the gauntlet and fly with it. Firefly Bio, assemble.

Instead of synchronizing the timing of a heartbeat, Impulse Dynamics' implant delivers electric signals that strengthen the heart's contractions.

With another quarter exceeding analysts’ expectations, Blueprint Medicines has raised its peak sales estimate for rare disease drug Ayvakit to $2 billion.

Aurinia Pharmaceuticals searched long and hard for a potential buyer, but faced with a lack of serious offers the biotech has resorted to trimming its workforce by a quarter and cleaning out its R&D pipeline.

As Alkermes enters 2024 as a “pure-play neuroscience company”—as described by CEO Richard Pops on a conference call on Thursday—much will depend on the success of new schizophrenia and bipolar disorder drug Lybalvi. With the company revealing fourth-quarter sales of $56.2 million for Lybalvi, the olanzapine and samidorphan treatment is continuing its upward trajectory, helping trigger a 10% increase in the company's shares.